Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

AlcaSynn Pharmaceuticals

Request full access

Drug development company focusing on small molecules of the morphinan group. In 2006 AlcaSynn was acquired by Sanochemia Pharmazeutika

Innsbruck, AustriaFounded 2004Biotech & Life Sciences

About AlcaSynn Pharmaceuticals

AlcaSynn Pharmaceuticals GmbH, established in Innsbruck, Austria, operates as a drug development company with a focus on morphinan-based therapeutics. Founded in 2002 by Professor Dr. Helmut Schmidhammer and Dr. Johannes Schütz, the firm specializes in the preclinical and clinical development of highly potent opioid and non-opioid drugs. The company's core competency lies in the medicinal chemistry of morphinans, possessing a diverse portfolio of drug candidates aimed at various medical indications.

In June 2006, Sanochemia Pharmazeutika AG acquired a 60% majority stake in AlcaSynn, a transaction valued at 12 million euros. This strategic partnership provided Sanochemia with access to AlcaSynn's extensive technological base and development resources in pain management and central nervous system (CNS) disorders. AlcaSynn collaborates with other pharmaceutical companies to develop drugs based on synthetic morphinan derivatives. These compounds are designed for the treatment of conditions such as pain, inflammation, Parkinson's, and Alzheimer's disease. The business model centers on research and development, aiming to create novel opioid analgesics with improved efficacy and reduced side effects compared to traditional options like morphine.

The company's product development pipeline is built upon targeted molecular modifications of the morphinan scaffold. This approach aims to create multifunctional ligands that can target multiple opioid receptors, offering a potential alternative to analgesics that selectively target the mu-opioid receptor. By focusing on specific chemical modifications, AlcaSynn works to discover opioid analgesics with more favorable pharmacological properties. At the time of the acquisition by Sanochemia, AlcaSynn held a patent portfolio consisting of 13 awarded patents with an additional 26 pending.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
51.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Developer Tools, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Aug 2006 $13M $53M Undisclosed —
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

AlcaSynn Pharmaceuticals website traffic

Latest recorded traffic for AlcaSynn Pharmaceuticals is 1.5K monthly website visits, up 120.6% over the last three months.

Latest monthly visits1.5K 3-month web change+120.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

AlcaSynn Pharmaceuticals in the Innsbruck ecosystem

Live from Dealroom

The AlcaSynn Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇦🇹 Austria · Innsbruck HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about AlcaSynn Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See AlcaSynn Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.